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Abstract—Magnetic resonance imaging (MRI) has become
one of the most important diagnosis tools available in
medicine. Typically MRI is not capable of sensing biochem-
ical activities. However, recently emerged activatable MRI
contrast agents (CAs), whose relaxivity is variable in
response to a specific parameter change in the surrounding
physiological microenvironment, potentially allow for MRI
to indicate biological processes. Among the various factors
influencing the relaxivity of a CA, the number of inner-
sphere water molecules (q) directly coordinated to the metal
center, the residence time of the coordinated water molecule
(sm), and the rotational correlation time representing the
molecular tumbling time of a complex (sR) contribute
strongly to the relaxivity of an activatable CA. Tuning the
ligand structure and properties has been the subject of
intensive research for activatable MR CA designs. This
review summarizes a variety of activatable MRI CAs
sensitive to common variables in microenvironment in vivo,
i.e., pH, luminescence, metal ions, redox, and enzymes, etc.,
with emphasis on the influence of ligand design on param-
eters q, sm, and sR.
Keywords—Magnetic resonance imaging (MRI), Contrast
agent, Relaxivity, Gadolinium, Activatable, Responsive.
INTRODUCTION
Since the first inception of X-ray technology for
medical imaging over a century ago, many non-inva-
sive imaging methodologies have been developed and
applied to biomedical science with the help of the sig-
nificant advances in electronics, information technol-
ogy, and nanotechnology.22,73,86 Today imaging has
become an indispensable tool in laboratory research,
clinical trials, and medical practice. Because of
advantages of high spatial resolution, the best soft-
tissue contrast in all currently available imaging
modalities, low toxicity, and the absence of ionizing
radiation, magnetic resonance imaging (MRI) has been
singled out as the in vivo diagnostic technology for the
next generation.46,84,88
MRI provides anatomical images by measuring
proton (1H) relaxation processes of water and soft
tissues in biological systems.12 The spinning of the 1H
nucleus generates a weak magnetic dipole. In thermo-
dynamic state, all the nuclear dipoles are oriented
randomly thus the net magnetic moment is zero. When
an external field B0 is applied, the
1H nuclei experience
a torque which forces them ‘‘align’’ with the field in
two separate, quantized energy states. The energy dif-
ference of the two quantized states (DE) is a function of
the gyromagnetic ratio of the spin (c), reduced Planck’s
constant ðhÞ; and external magnetic field (B0) (Eq. 1).
DE ¼ chB0 ð1Þ
The frequency of the energy (m) (Eq. 2) required for
an NMR transition is commonly represented by
Larmor frequency (x) (Eq. 3).
m ¼ cB0=2p ð2Þ
x ¼ 2pm ¼ cB0 ð3Þ
The energy required for a 1H nuclear spin
(c = 42.576 MHz T21) transition at currently avail-
able external fields (up to 15 T) is at the magnitude of
10225 J which corresponds to radiowaves in the elec-
tromagnetic spectrum. The low energy of NMR means
it is a very insensitive technique. When a resonant
radio frequency (RF) transverse pulse is perpen-
dicularly applied to B0, it causes resonant excitation of
the magnetic moment precession into the perpendicu-
lar plane. Once the RF perturbation is removed,
the dipoles return or ‘‘relax’’ to thermodynamic
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equilibrium. The relaxation behavior of the dipoles is
described by longitudinal T1 relaxation (loss of energy
from the excited state to its surroundings, termed as
spin–lattice interaction) and transverse T2 relaxation
(random variations in local field strength, caused by
neighboring spins, de-synchronize the signals, termed
as spin–spin interaction).13
The signal emitted by the hydrogen nuclei during
relaxation is referred to as the free-induction decay
(FID) response signal. To produce an MRI image, the
FID resonance signal must be encoded from each
dimension. The encoding in the Z axial direction of B0
is accomplished by adding a gradient magnetic field to
B0. The gradient causes the Larmor frequency x to
change linearly in the B0 direction. A tiny axial slice in
that direction is then selected and x of hydrogen nuclei
in the slice is assumed to be identical. The spatial
reconstruction of each axial slice is realized by using
frequency and phase encoding. A gradient Gy is
applied, causing the resonant frequencies of the nuclei
in the slice to vary according to their position in the Y
axial direction. Gy is then removed and another gra-
dient Gx is applied perpendicular to Gy. As a result, the
resonant frequencies of the nuclei vary in the X axial
direction due to Gx and have a phase variation in the Y
axial direction due to the previously applied Gy.
Therefore, samples are encoded by frequency in the X
axial direction and by phase in the Y axial direction. A
Fourier Transform is then used to transform the
encoded image to a plane image.13
Intensity of signals from each volume element
(voxel) of a given tissue type is a function of proton
density of the tissue. The higher the proton density, the
stronger the FID response signal. The MR image
contrast also depends on tissue-specific parameters T1
and T2. When MR images are acquired, the RF pulse is
repeated at a predetermined rate. The period of the RF
pulse sequence is the repetition time, TR. The time
between which the RF pulse is applied and the
response signal is measured is the echo delay time, TE.
By adjusting TR and TE the acquired MR image can
possess contrast for different tissue types.13
Because the endogenous MR differences among
various types of tissues can be small, a contrast agent
(CA) is often used in MRI to provide additional con-
trast to distinguish a target tissue from its surround-
ings. Clinical CAs are in the form of either
paramagnetic gadolinium (Gd3+) or manganese
(Mn2+) chelates, or superparamagnetic iron oxide
(SPIO) and ultrasmall superparamagnetic iron oxide
(USPIO) nanoparticles that take effect by catalytically
shortening the relaxation times of bulk water protons.
Paramagnetic chelates increase the longitudinal relax-
ation rate (R1) by roughly the same extent as that
they increase the transverse relaxation rate (R2).
They exhibit ‘‘positive’’ (bright) contrast where they
localize and are referred to as T1 agents. In contrast to
paramagnetic chelates, iron oxide nanoparticles in-
crease the transverse relaxation rate (R2) to a much
greater extent than they increase the longitudinal
relaxation rate (R1). They exhibit ‘‘negative’’ (dark)
contrast where they localize and are referred to as T2
agents.34
The proportion of clinical MRI protocols using CAs
has increased rapidly, from approximately 30% in 1999
to a current estimation of 40–50%.16,85 ‘‘Positive’’ CAs
generally are more preferable in the clinic compared to
those that induce ‘‘negative’’ contrast or signal loss. It is
easier to ascribe signal enhancement, rather than signal
loss, to CA accumulation in tissue because there are
potentially other sources of signal loss in MR images
beyond iron oxide nanoparticle accumulation.25 The
majority of MRI CAs currently used in the clinic are
chelates of Gd3+ ions, as shown in Fig. 1 and Table 1,
because the lanthanide ion has a largemagneticmoment
and long electronic relaxation time, therefore offering
excellent ‘‘positive’’ image contrast.16,38
The most important property of a CA is its
relaxivity (r) that reflects the ability of the CA to
generate imaging signal contrast. The r1 relaxivity of
a CA is the agent’s ability to affect the longitudinal
relaxation rate r1 (=1/T1) of water protons and its
value is expressed in mM21 s21.77 According to
the Solomon–Bloembergen–Morgan (SBM) theory,
relaxivity originates from the dipole–dipole interac-
tions between the proton nuclear spins and the fluc-
tuating local magnetic field caused by the unpaired
electron spins of the paramagnetic substance.17
Relaxivity depends on a number of factors including
the number of inner-sphere water molecules (q) di-
rectly coordinated to the metal center, the residence
time of the coordinated water molecule (sm), the
rotational correlation time representing the molecular
tumbling time of a complex (sR), electronic parame-
ters, paramagnetic metal ion-proton distance, external
field, and temperature.15,17,38,77 The water molecules
coordinated to the metal center in Gd-based clinical
CAs are defined as the inner-sphere or the first-sphere
water molecules (Fig. 2). The Gd CAs have typical
values of more than 100 ns for sm and 0.1 ns for sR,
which results in a low r1 relaxivity (~5 mM21 s21
at 1.5 T) because the optimal values of these agents at
1.5 T should be approximately 10 ns for sm and at
least 10 ns for sR according to SBM theory. The s
values can be altered via ligand designs that allow
faster water exchange and slower molecular tumbling.
The tuning of the ligand structure has been the sub-
ject of intensive research for the past two decades
because an increase in the relaxivity allows for a
dramatic decrease in the application dose.15,26,85,87
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Most of clinically approved Gd CAs are extracel-
lular fluid (ECF) MRI CAs. Their low molecular
weight allows them to equilibrate rapidly between the
intravascular and interstitial space and then clear
almost exclusively by renal filtration on the time scale
of a few hours. The ECF CAs are generally non-
specific. They do not interact specifically with any
type of cells, though their distribution in the body is
far from homogeneous.34 MRI with ECF CAs is
typically used for a whole body scan, and is not
capable of sensing biochemical activities. During the
last decade, new types of CAs have been devel-
oped—targeted CAs that accumulate in specific tis-
sues and organs and allow for an improved diagnosis
of these body regions,41,42,79,82,83 as well as activatable
CAs whose relaxivity reports about a specific
parameter of the microenvironment in which they
distribute and allow for MRI to indicate biological
processes.10,27,35,36,41,49,64,67,68,75 Most, though not all,
activatable CAs reported are typically small molecu-
lar Gd chelates. The principle behind the design of
such CAs is that the access of water molecules to the
first coordination sphere of the chelated gadolinium
ion is controllable through intramolecular rearrange-
ment of the CA, leading to a change in relaxivity. The
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FIGURE 1. Chemical structures including one coordinated water molecule, chemical names, and trademark names of Gd-based
MRI CAs approved for clinical use in the EU and USA.
FIGURE 2. Schematic illustration of molecular parameters
influencing relaxivity of Gd-based MRI CAs in solution. Image
modified from Fig. 2 in Werner et al..
TABLE 1. Properties of clinically approved, Gd-based MRI CAs.2,85
Trade name Type
Plasma relaxivity
(1.5 T, 37 C)
(mM21 s21)
Log KML Clearance
Osmolality
(Osm/kg
H2O) Locationr1 r2
Magnevist Ionic 4.1 4.6 22.1 Renal 1.96 EU, USA
Omniscan Neutral 4.3 5.2 16.9 Renal 0.79 EU, USA
Optimark Neutral 4.7 5.2 16.6 Renal 1.11 EU, USA
Dotarem Ionic 3.6 4.3 25.8 Renal 1.35 EU
Prohance Neutral 4.1 5.0 23.8 Renal 0.63 EU, USA
Gadovist Neutral 5.2 6.1 21.8 Renal 1.60 EU
Multihance Ionic 6.3 8.7 22.6 Renal/Hepatic 1.97 EU, USA
Envist Ionic 6.9 8.7 23.5 Renal/Hepatic 0.69 EU, USA
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percent change in relaxivity before and after stimu-
lation is the most important factor in evaluating the
efficiency of an activatable MRI CA. Among various
factors influencing the relaxivity of a CA, q, sm, and
sR contribute the most to the relaxivity of an acti-
vatable CA.41 Increasing the number of protons
coordinated to the paramagnetic ions (q), increasing
size, and increasing exchange rate are all known to
increase relaxivity.15 Herein, we briefly introduce
recent advances in activatable MRI CAs sensitive to
common variables in biological microenvironment,
i.e., pH, bioluminescence, metal ions, redox, and
enzymes.
pH-RESPONSIVE MRI CAs
Decreased extracellular pH has been observed in
cancer and various ischemic diseases and could be a
biomarker for early detection or to monitor treatment
efficacy.61 Thus, the ability to non-invasively and reli-
ably assess tissue pH is of great interest to scientists
and clinicians. One of the earliest and most extensively
characterized pH-sensitive MRI CAs, Gd-DOTA-
4AmP52, was developed by Sherry and coworkers.90
The agent, depicted in Fig. 3, consists of Gd3+ che-
lated by an amido-phosphonate appended derivative
of DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-
tetraacetic acid). pH sensing for this agent involves an
altered proton exchange mechanism due to proton-
ation of the phosphonate appendages that presents a
1.5-fold increase in r1 over the pH range 9.5–6. The
four phosphonate groups have pKas in the range 6.5–8
that, upon protonation, provide hydrogen-bond
donors to the Gd3+ bound water molecule allowing
catalytic exchange of inner-sphere bound water pro-
tons with those of bulk water. A drawback of this
system for pH mapping is that the tissue concentration
of CA must be known for quantitation.
In response to this obstacle, Gillies and colleagues
applied the Gd-DOTA-4AmP52 and a similar, yet
pH-insensitive Gd3+-based agent, Gd-DOTP52
(Fig. 3), sequentially (approx 1 h apart), to a rat tumor
model.33 With the assumption that the similar CAs had
comparable biodistribution and pharmacokinetics, the
researchers inferred the concentration of Gd-DOTA-
4Amp52 based on the observed concentration of
Gd-DOTP52. The image intensity differences between
the agents at maximum enhancement were used to
successfully map extracellular tissue pH in the rat gli-
oma model. Another solution for the quantitation di-
lemma was recently reported by Caravan and
coworkers.32 Rather than injecting two CAs, the Gd-
DOTA-4AmP52 was modified to incorporate a fluo-
rine radiotracer that allows quantitation via positron
emission tomography (PET) imaging. The fluorine
modified CA (Fig. 3) retained its pH-responsive
relaxivity measuring between 3.9 mM21 s21 at pH 6.0
and 7.4 mM21 s21 at pH 8.5. Dual-modality imaging
of this activatable agent permits simultaneous quanti-
fication of the CAs tissue concentration and relaxivity
thus providing a region’s pH based on the linear pH-r1
relationship.
Aime and coworkers investigated a responsive
Gd agent that measures pH in a concentration-
independent fashion through r2/r1 ratiometric analysis.
3
The Gd-DOTA functionalized polypeptide (poly-
L-ornithine), shown in Fig. 4a, assembles randomly at
low pH or into an ordered helix at higher pH; this
pH-dependent change in conformation affects the
rotational mobility of the complex yielding variation in
the r2/r1 ratio. Similarly, Sherry and colleagues
reported an MRI CA that utilizes altered molecular
tumbling and proton exchange kinetics to magnify
pH sensitivity.4 The relaxivity and responsiveness
of the previously discussed, small-molecule agent,
Gd-DOTA-4AmP52, was improved upon through
conjugation to the surface of a PAMAM dendrimer
(Fig. 4b) thus producing a macromolecular sensor with
~96 pH-responsive Gd chelates. This approach affect-
ing both molecular tumbling and exchange kinetics of
inner- and outer-sphere water molecules provided
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FIGURE 3. Structure of MRI CAs: Gd-DOTA-4AmP, Gd-DOTP, and dual-modality PET/MRI CA: Gd-DOTA-4Amp-F.
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increased overall relaxivity by a factor of nearly 5 and
enhanced pH responsiveness for the dendrimer by
means of a greater amplitude change in r1 (a 2.2-fold
increase was observed over the pH range 9.5–6) over
the measured pH range. While the large size and
~140 kDa molecular weight of the agent positively
affected its pH response, they may prove detrimental
to its effectiveness in vivo. Dendrimers have the
potential for toxicity due to slow clearance through the
liver, and they may not diffuse from the vasculature
as easily as small molecule CAs. Further experiments
are needed to assess pharmacokinetics and biodistri-
bution of the dendrimer based CA.
Two unconventional, Gd-based pH-responsive CAs
were reported by Wilson, Toth, and coworkers in the
form of gadofullerenes76 and gadonanotubes.37 The
water-soluble gadofullerenes, Gd@C60[C(COOH)2]10
and Gd@C60(OH)x, were shown to exhibit a
pH-dependent reversible aggregation that results in
variation of the rotational correlation time and thus
variable relaxivity.As pHwas decreased, the researchers
observed aggregation of the agent by dynamic light
scattering (DLS) size measurement. Correspondingly,
the proton relaxivities of Gd@C60[C(COOH)2]10 and
Gd@C60(OH)x increase by a factor of 3.8 and 2.6,
respectively, with decreasing pH over the range 12–2.
These gadofullerenes offer two distinct advantages to-
wards translating them into clinically viable MRI CAs
for pH sensing. First, water-soluble fullerenes have
shown the ability to cross cell membranes, and second,
the entrapment of Gd3+ within the fullerene cage pre-
vents the toxicity observed from free, unchelated Gd3+
ion. Gadonanotubes, represented in Fig. 5, are
20–80 nm segments of single-walled carbon nanotubes
that have sidewall defects in which 3–10 Gd3+ ions
cluster. The short nanotubes were prepared by a chem-
ical cutting process that creates defects in which Gd3+
ions are loaded with chloride as counter ions. The
gadonanotubes display remarkably high relaxivity
(180 mM21 s21 at 1.5 T) compared to current clinically
used MRI CAs. In addition, the authors report a >
3-fold increase in relaxivity observed from pH 8.3 to 6.7.
While the mechanism of the pH-dependent contrast
enhancement is unclear, experiments verified that Gd3+
ion are not leaked from the nanotube clusters upon pH
cycling or physiological challenges such as phosphate
buffer solution (PBS), bovine serum, or heat. These
results show potential for development of gadonanotu-
bes as efficient, ultra-sensitive pH-responsiveMRICAs.
LIGHT-RESPONSIVE MRI CAs
One of the more recent and novel advances in the
field of activatable MRI probes is the development of
light-responsive CAs. Bioluminescence imaging has
found wide use in cell and molecular biology. Scientists
and clinicians are able to use luminescence from
markers such as green fluorescent protein or the
luciferase system as reporters of gene expression or for
cell-tracking purposes.28 While optical imaging of
bioluminescence offers the benefit of high sensitivity, it
suffers the drawback of limited tissue penetration
depth. Therefore, a photo-responsive, reversibly
FIGURE 4. Structures of the macromolecular, pH-sensitive CAs (a) (Gd-DOTAam)33-Orn205 and (b) Gd-DOTA-4AmP-PAMAM
dendrimer. Graphic (a) modified from Chart 1 in Aime et al.3 Graphic (b) modified from Ali et al.4.
FIGURE 5. Pictorial representation of Gd3+ ions ( ) within
the sidewall defects of a nanotube. Gd clusters measure
roughly 1 3 5 nm with 3–10 Gd3+ ions per cluster. Graphic
from Fig. 1 in Hartman et al.37.
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activatable MRI CA would provide a means of imag-
ing such bioluminescence in deep tissues. Louie and
coworkers have developed a series of MRI CAs that
respond to visible and UV light. Utilizing light-
responsive molecular switches from the spiropyran
family of compounds, they have developed both T1
78,81
and T2
57 CAs that can modulate MR signal with light
stimulus.
The T1 agents consisted of either a single nitro or
dinitro-spiropyran derivative that was tethered to a
DO3A chelated Gd3+ ion. Varying degrees of light
response were observed depending on the spiropyran
moiety that the agent possessed. The ‘‘single nitro’’
version showed a 21% decrease in relaxivity (3.72–
2.93 mM21 s21) in solution studies upon visible light
irradiation following storage in the dark. Whereas, the
dinitrospiropyran-Gd-DO3A presented an 18% de-
crease in relaxivity with white light stimulus (2.51–
2.05 mM21 s21). Both agents exhibited reversibility
with UV irradiation (at 365 nm) or storage in the dark.
The observed r1 modulation was attributed to a change
in hydration state, q, of the Gd3+ ion due to the ability
of the tethered spiropyran to block water access upon
absorbance of visible light. Beyond the light stimulated
response, the authors note that the dinitrospiropyran-
GdDO3A agent also possessed a novel NADH
response that is discussed further in ‘‘Redox potential
responsive MRI CAs’’ section of this review.
Most recently, the Louie group reported an acti-
vatable MRI T2 agent, CLADIO-NH-SP, that modi-
fies relaxation time through reversible aggregation of
magnetic nanoparticles (Fig. 6).57 This probe employs
a spiropyran derivative that is covalently bound to the
surface of cross-linked and aminated dextran sulfate
coated iron oxide nanoparticles. The spiropyran
derivative changes conformation reversibly between
hydrophobic and hydrophilic isomers with UV and
visible light irradiation; this conformation switching
directs the aggregation and dispersion of the nano-
particles, thus regulating T2 relaxation time. The
authors observed nanoparticle aggregation by DLS
size measurement and a 34% decrease in T2 relaxation
time upon visible light irradiation. In addition, the
reported absorbance maximum of the spiropyran ter-
minated CA is 563 nm which provides overlap with the
emission of firefly luciferin; therefore, this light-
responsive MRI probe shows promise for development
as a non-invasive reporter of gene expression.
METAL ION-RESPONSIVE MRI CAs
Metal ions play significant roles in biological sig-
naling events, redox homeostasis, and metabolism.
Therefore, it is not surprising to see research effort in
the last decade towards development of activatable
MRI agents responsive to biologically relevant metal
ions such as Ca2+, Zn2+, Fe2+, and Cu+/2+ ions.
Meade and colleagues reported the first Ca2+-respon-
sive MRI CA consisting of two Gd-DO3A chelates
connected by a modified BAPTA (1,2-bis(o-amino-
phenoxyl)-ethane-N,N,N¢,N¢-tetreaacetic acid) linker
(Fig. 7).45 In the absence of Ca2+, the carboxylate
arms of the BAPTA moiety bind the chelated Gd3+
yielding a relaxivity of 3.26 mM21 s21. In the presence
of Ca2+, the BAPTA selectively binds Ca2+ and frees
up Gd3+ binding sites for bulk water, resulting in a
relaxivity increase to 5.76 mM21 s21. The agent’s
BAPTA linker possesses a preference for Ca2+ over
Mg2+ with a binding affinity in the low micromolar
range which makes this CA capable of detecting
intracellular Ca2+. Since the Meade group contribu-
tion, several other lower affinity Ca2+-sensitive CAs
have been reported that utilize dual Gd-DO3A chelates
with varying linkers such as BAPTA bisamide,29
EDTA,53 DTPA,53 and EGTA.5 With millimolar
FIGURE 6. Mechanism of reversible aggregation for light-responsive CLADIO-NH-SP. Image from Scheme 1 in Osborne et al.57.
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binding affinities, these agents show promise as extra-
cellular Ca2+ sensors.
Dhingra, Logothetis, and coworkers report an MRI
CA, Gd-DOPTRA (Fig. 7), which provides nearly
100% contrast enhancement upon coordination of
Ca2+ (3.5 mM21 s21 in the absence of Ca2+ and
6.9 mM21 s21 with addition of Ca2+).29 Gd-DOP-
TRA is composed of a Gd-DO3A unit linked to a
micromolar affinity Ca2+ chelator, APTRA (o-amino-
phenol-N,N,O-triacetate). This agent offers the bene-
fits of micromolar Ca2+ binding in a more condensed
structure than those previously developed; however,
specificity for Ca2+ is to some extent compromised as
this agent produces relaxivity changes in response to
Mg2+ and Zn2+, as well. Kubicek et al. recently
reported another activatable CA, Gd-do3apBP, con-
structed of a single Gd-DO3A core with a bisphosph-
onate arm (Fig. 7).44 The bisphosphonate group
coordinates the divalent metal ions Ca2+, Mg2+, and
Zn2+ in an apparent coordination oligomer resulting
in increases in r1 up to 200–500%. This staggering
relaxivity enhancement is observed upon addition of
3 equiv. of metal ions to a 2 mM CA solution in a
pH-dependent fashion that varies with the metal spe-
cies. The authors note that the Zn2+ concentration
used is not in the biologically relevant range
(<0.1 mM), though Ca2+ and Mg2+ sensing is feasi-
ble though specificity is not yet ideal.
Beyond the T1 Gd-based probes, Jasanoff and
coworkers report calmodulin (CaM) modified super-
paramagnetic iron oxide (SPIO) nanoparticles as
Ca2+-responsive MRI T2 agents.
6 CaM, a calcium
signaling protein, binds target peptides in response to
Ca2+ levels. By applying CaM- and peptide-conju-
gated SPIOs (20–100 nm) in a 3:1 ratio, the researchers
observed significant changes in T2 relaxivity through
aggregation of the SPIOs resulting from Ca2+ induced
cross-linking of CaM and target peptides. This CA was
found to detect micromolar Ca2+ concentration in an
appropriate range for intracellular Ca2+ sensing.
Furthermore, the sensitivity can be manipulated by
structurally modifying the CaM or target peptides.
Currently, the most significant hurdle to biological
application of the existing agent is the inability to cross
cellular membranes. Further surface modification is
required to address this issue.
Similar to those of Ca2+, Gd-DO3A based agents
selectively responsive toZn2+have also been developed.
TheMeade groupproduced twoMRICAswith>100%
increases in relaxivity upon Zn2+ detection. Gd-daa350
and Gd-apa348 provide selective Zn2+ binding over
other biologically abundant cations such as Ca2+,
Mg2+, Na+, and K+. Recently, the Zn2+-responsive
CA, Gd-DOTA-diBPEN, has been found to increase in
relaxivity 165% (6.6–17.4 mM21 s21) due to an inter-
action with human serum albumin (HSA).31 In the
absence of HSA, the relaxivity increase is a modest 20%
upon Zn2+ detection, suggesting sR modulation.
Gd-DOTA-diBPEN does not respond to Ca2+ or
Mg2+, yet can detect Zn2+ down to 30 lM in the
presence of HSA as observed in in vitro imaging studies.
Though iron-sensing CAs have not been character-
ized in literature, several Gd chelates that also coor-
dinate Fe with corresponding relaxivity increases have
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been reported.1,24,58,59 For instance, Parac-Vogt et al.
describe an MRI probe, Gd-DTPA-phen, that self-
assembles 3:1 with an Fe2+ ion.58 The supramolecular
complex, [(Gd-DTPA-phen)3Fe]
2, has a relaxivity of
9.5 mM21 s21 as compared to 3.9 mM21 s21 for
Gd-DTPA. Similarly, Desreux and coworkers reported
a 77% increase in relaxivity upon coordination of
Fe2+ with three GdPhenHDO3A complexes.59 Neither
of these cases address the sensitivity or specificity for
Fe2+ over other metal ions so further exploration into
their suitability as Fe-sensitive CAs is needed.
Cu-sensing agents are among the newest metal ion-
responsive MRI CAs. Chang and coworkers recently
reported a series of sensors that utilize a Gd-DO3A
core with a Cu ion binding thioether pendant arm
(Fig. 8).65 These agents provide r1 modulation through
altered hydration state of the Gd3+ ion. In the absence
of copper, the pendant arm appears to block water
access to the Gd core yielding q = 0.3; upon addition
of 1 equiv. Cu+, q increases to 2. The most responsive
of these agents yields a 360% increase in relaxivity
upon Cu+ binding (1.5–6.9 mM21 s21 with Cu+). In
addition, the Chang group has developed a sensor that
can detect Cu2+ with high affinity through inclusion of
an O donor in the pendant arm (Fig. 8c).65 These CAs
offer significant benefits over those previously reported
for Cu2+ detection in that they possess picomolar
range Cu+/Cu2+ binding affinity with high specificity
over other biologically endogenous metal ions. In the
realm of responsive T2 agents, Patel et al. reported
SPIO nanoparticles surface-modified with DOTA for
the chelation of Cu2+.60 These agents were developed
as dual-modality PET/MRI CAs, but a strong increase
in r2 relaxivity (~300%) upon coordination of Cu2+
ions points to potential use as activatable MRI CAs
responsive to micromolar Cu2+ concentration. The
authors speculate as to the mechanism causing r2
increase, but indicate that aggregation of the nano-
particles is not observed. The association of water
molecules at the DOTA bound Cu2+ ion may facilitate
transmission of the magnetic induction of the SPIO to
bulk water, or the surface modification could possibly
shorten the residence lifetime of coordinated water.
REDOX POTENTIAL-RESPONSIVE MRI CAs
Redox reactions are widely seen in biochemical
activities. Disruption of redox homoeostasismay lead to
many pathological conditions, such as atherosclerosis,
stroke, Alzheimer’s disease, Parkinson’s disease, and
cancer, etc.39 However, non-invasive observation of
intracellular redox activities and their relationship to
physiological function is still a challenge for molecular
imaging, most likely due to the lack of appropriate
probes responsive to redox potential.14,40,51
Louie and co-workers have developed activatable
MRI CAs sensitive to reduced nicotinamide adenine
dinucleotide (NADH), the principal electron donor for
the respiratory chain in mammalian cells.43,80,81 In the
first generation agent a spirobenzopyran molecule,
which is responsive to changes in light and electrical
activities,7,63,91 was coupled to Gd-DO3A (DO3A:
1,4,7,10-tetraazacyclododecane-1,4,7-trisacetic acid).
As described earlier in the paper, when photo-stimu-
lation was applied, the structural change of the spiro-
benzopyran moiety in the resultant agent caused the
two isomers to have different contrast enhancement
properties for MRI. However, the CA was not
responsive to electrical activity or redox potential.78 By
adding a strong electron-withdrawing nitro group to
the indole ring, the r1 relaxivity of the resultant dini-
trospiropyran-Gd-DO3A is found to be responsive to
both light and NADH. When in the dark, the CA is in
its open (MC) form and has an r1 relaxivity of
2.51 mM21 s21. After irradiation with visible light or
mixing with NADH, the CA experiences a color
change and its r1 relaxivity decreases to 2.05 and
1.86 mM21 s21, respectively.81 The second genera-
tion agent employs spironaphthoxazines instead of
FIGURE 8. Gd-DO3A-based MRI CA. (a) with a Cu+-binding thioether pendant arm demonstrating; (b) r1 relaxivity increases (with
corresponding percent increase given) to 1 equiv. of Cu+ in the presence of various biological anions. White bars represent CA
relaxivities in the absence of Cu+ while the black bars represent relaxivities with addition of Cu+ (60 MHz, 37 C, pH 5 7.4); (c)
shows the Cu2+ activated CA. Graph from Fig. 7 in Que et al.65.
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spirobenzopyran.23,89 In the dark the agent has an r1
relaxivity of 5.58 mM21 s21 and an average of 1.26
water molecules coordinated with the Gd(III). In the
presence of NADH, as shown in Fig. 11, the agent
undergoes an isomerization and its hydration number
(q) increased to 2.01, which leads to an r1 relaxivity
increase of 54%. The T1 value can be fully restored
after applying hydrogen peroxide to the system.
Macrophages are incubated with spirooxazine-
Gd-DO3A, then exposed to externally applied NADH.
Cells exposed to NADH show substantial contrast
enhancement, as shown in Figs. 9a and 9b.
Unlike the Gd agents described above whose redox
reactions take place on the ligand, redox reactions of
activatable iron (Fe) agent occur directly at the metal
center. Jasanoff and coworkers report injection of iron-
containing hemoglobin (Hb) into blowflies; they found
that the Hb can permeate through relatively dense
neural tissue without obvious disruption to physiology
and the oxidation state ofHb is dependent on the partial
pressure of oxygen, pO2. Oxygen is an important
parameter in living systems. Variations in pO2 have been
relevant to many diseases, such as stroke and
tumors.52,62 Hb-injected flies show approximate 40–50%
changes in signal intensity when external O2 levels are
manipulated artificially from 0 to 21%, because the iron
in the porphyrin ring of Hb changes in redox state from
diamagnetic Fe(II) to paramagnetic Fe(III) in the pres-
ence of O2. In vivo T2-weighted MRI shows that a small
amount of Hb is able to produce substantial
pO2-dependent signal contrast, and the contrast changes
can be roughly calibrated if necessary.74
ENZYME-RESPONSIVE MRI CAs
The enzymatically modulated MRI CAs could
provide an effective means of measuring enzyme
activity, detecting enzyme location, and assaying gene
expression. Meade and coworkers developed the first
example of enzyme-sensitive MRI CA and demon-
strated the principle of enzymatic activation of an MRI
CA by beta-galactosidase.47,54 More recently, Meade
group developed a Gd-DO3A derivative which shows
relaxivity change in the presence of b-glucuronidase.30
As shown in Fig. 10, the agent bears a pendant
b-glucuronic acid moiety, the substrate of b-glucu-
ronidase, on an arm of DO3A. In the presence of bo-
vine liver b-glucuronidase, an ether bond of the agent
was enzymatically cleaved, resulting in a self-immo-
lating reaction passing through the spacer until the
breakage of the amide bond (red arrow), and restrict-
ing water access to the paramagnetic ion. In compar-
ison with the original beta-galactosidase agent, the
resultant 2-aminoethyl-Gd-DO3A has an extra amine
group (blue arrow) coordinated to the metal center,
thus is expected to have a lower q number and relax-
ivity value. However, the relaxivity changes of the
enzymatic hydrolytic reaction markedly depended on
buffer composition employed: the relaxivity increased
in a buffer mimicking in vivo anion concentrations by
17%, while the relaxivity decreased by 27% for the
same experiment in human blood serum.
Besides hydrolases, oxidoreductases also have been
targets in the exploration of enzyme-sensitive para-
magnetic CAs. A MR signal amplification strategy has
been developed based on oxidoreductase-mediated
polymerization of paramagnetic Gd substrates
into oligomers of higher magnetic relaxivi-
ty.8,9,11,18–21,55,66,67,69–72 Benzene-1,2-diol which is
known to be a substrate of oxidized peroxidases was
linked to a Gd-DOTA chelate, and the resultant agent
acted as a monomer (Fig. 11a). In the presence of
peroxidase, the monomers were induced to form rad-
icals that trigger the rapid condensation into para-
magnetic oligomers leading to a threefold increase in r1
FIGURE 9. The structural and hydration number (q) changes in the first coordination sphere of Gd(III) of spirooxazine-Gd-DO3A
triggered by NADH and hydrogen peroxide. T1-weighted MRI images of (a) spirooxazine-Gd-DO3A and (b) the mixture of spi-
rooxazine-Gd-DO3A and NADH (Gd:NADH 5 1:1), in P388D1 murine macrophages. Images modified from Scheme 2 and Fig. 5 in
Tu et al.80.
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relaxivity due to an increase in sR. By this signal
amplification mechanism, horseradish peroxidase
(HRP) could be detected in the nanomolar range. In
vivo MRI was also performed to detect E-selectin
expression on human endothelial cells in culture by
using a highly specific first antibody, followed by a
secondary antibody conjugate with HRP.8
By substituting the catechol moiety with a serotonin
moiety (Fig. 11b), the Gd(III) chelate was oriented to
be responsive to myeloperoxidase (MPO), a key-mar-
ker of inflammation processes involved in numerous
pathologies. Serotonin is a naturally occurring neuro-
transmitter that functions as a reducing substrate for
MPO. The agent is efficiently polymerized in the
presence of human neutrophil MPO resulting in a
70–100% increase in proton relaxivity.20 The MPO-
enhanced MRI signal was also obtained when using
Gd-DTPA bearing either tyramide (Fig. 11c or
5-hydroxytryptamide-(serotonin) (Fig. 11d) groups.70
The activation involves the formation of a radical
species that can proceed differently depending on the
considered complex. Two mechanisms have been sug-
gested.71 One is related to the oligomerization of the
complex and the other is related to the formation of
cross-linked structures with proteins, as shown in
Fig. 12.However, it is also found that sometimes theGd
agent may utilize both mechanisms when activated.71
The Gd-DTPA-serotonin, referred as MPO-Gd,
was further applied for in vivo MRI of ischemic in-
jury of the myocardium which causes timed recruit-
ment of neutrophils and monocytes/macrophages,
which produce substantial amounts of local MPO.55
Myocardial infarction (MI) was induced by left
coronary artery ligation of normal (C57BL/6) mice.56
After 2 days coronary ligation, mice were scanned
before and up to 2 h after injection of equal doses
of MPO-Gd and control Gd-DTPA. The signal
enhancement was observable in the kinetic infarct at
10 and 30 min after injection of Gd-DTPA with peak
enhancement at 10 min, then completely returned to
the original status after 60 min. After injection of
MPO-Gd, the peak enhancement appeared at 60 min
and the signal intensity was significantly higher in
comparison with that of Gd-DTPA. The enhance-
ment was still observable even at 120 min after
injection.55
N
N
N
N
O
O
O
OH
O
O
H
NO
O
O
O
O2N
HO
HO
OH
OHO
N
N
N
N
O
O
O
O
O
O
NH2
HO
O2N
O
HO
HO
OH
OHO
OH
OH
Gd3+
Gd3+
CO2
β -glucuronidase
H2O
+
+ +
FIGURE 10. Schematic illustration of b-glucuronidase-catalyzed cleavage of a Gd-DO3A type chelate bearing the substrate of b-
glucuronidase.
N N
N N
O
O
O
O
O
O
Gd3+
H
N N
HO
O OH
OH
N N
N N
O
O
O
O
O
O
Gd3+
H
N N
HO
O NH
OH
N
N N
N
HOO
O
O O
N
H O
O
O
Gd3+ NH
OH
HN
HO
N
N N
N
HOO
O
O O
N
H O
O
O
Gd3+
HO OH
(a) (b)
(c) (d)
FIGURE 11. Schematic illustration of Gd chelates sensitive to myeloperoxidase (MPO).
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CONCLUDING REMARKS
During the last decade, emergence of suitable CAs
which report on physiological processes has expanded
the scope of MRI beyond anatomical and functional
imaging to also convey information at the cellular or
even molecular level. Though a variety of publications
have shown the great potential of activatable CAs to
report about changes of diagnostically relevant vari-
ables of physicochemical microenvironments in vitro,
so far only very few examples have moved into in vivo
studies. An active and effective collaboration between
chemists, biologists, and clinicians is particularly crit-
ical in bringing activatable CAs with outstanding
properties into realistic uses. Feedback from biologists,
imagers, and clinicians will be crucial for chemists to
design more versatile and controllably activatable CAs
whose structures can be readily and finely tuned to
undergo either intramolecular transitions or intermo-
lecular interactions resulting in greater relaxivity
changes in response to variables of physiological
microenvironments.
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